Compare MOLN & AIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOLN | AIRS |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | Switzerland | United States |
| Employees | 134 | N/A |
| Industry | | Medical/Nursing Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.4M | 122.6M |
| IPO Year | 2021 | 2021 |
| Metric | MOLN | AIRS |
|---|---|---|
| Price | $2.94 | $0.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $10.22 | $1.50 |
| AVG Volume (30 Days) | 1.7K | ★ 1.5M |
| Earning Date | 10-29-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $151,818,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.00 | $0.52 |
| 52 Week High | $5.36 | $5.79 |
| Indicator | MOLN | AIRS |
|---|---|---|
| Relative Strength Index (RSI) | 28.42 | 35.65 |
| Support Level | N/A | N/A |
| Resistance Level | $4.21 | $1.95 |
| Average True Range (ATR) | 0.11 | 0.19 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 9.27 | 22.52 |
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.